Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is -10.18% lower on its value in year-to-date trading and has touched a low of $15.19 and a high of $71.25 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ADPT stock was last observed hovering at around $57.89 in the last trading session, with the day’s loss setting it -4.78% off its average median price target of $70.00 for the next 12 months. It is also 28.23% off the consensus price target high of $74.00 offered by 8 analysts, but current levels are 11.48% higher than the price target low of $60.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $53.11, the stock is -11.96% and -12.79% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.29 million and changing -8.26% at the moment leaves the stock 8.95% off its SMA200. ADPT registered 98.17% gain for a year compared to 6-month gain of 30.14%. The firm has a 50-day simple moving average (SMA 50) of $61.42 and a 200-day simple moving average (SMA200) of $52.26.
The stock witnessed a -4.25% loss in the last 1 month and extending the period to 3 months gives it a 13.00%, and is -6.43% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.75% over the week and 5.70% over the month.
Adaptive Biotechnologies Corporation (ADPT) has around 622 employees, a market worth around $7.23B and $98.40M in sales. Distance from 52-week low is 249.64% and -25.46% from its 52-week high. The company has generated returns on investments over the last 12 months (-20.60%).
Adaptive Biotechnologies Corporation (ADPT) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Adaptive Biotechnologies Corporation (ADPT) is a “Buy”. 8 analysts offering their recommendations for the stock have an average rating of 1.60, where 1 rate it as a Hold and 0 think it is a “Overweight”. 7 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Adaptive Biotechnologies Corporation is expected to release its quarterly report on 05/18/2021 and quarterly earnings per share for the current quarter are estimated at -$0.41 with sales reaching $27.84M over the same period.The EPS is expected to shrink by -100.60% this year, but quarterly earnings will post 52.40% year-over-year. Quarterly sales are estimated to grow 29.30% in year-over-year returns.
Adaptive Biotechnologies Corporation (ADPT) Top Institutional Holders
303 institutions hold shares in Adaptive Biotechnologies Corporation (ADPT), with 7.19M shares held by insiders accounting for 5.16% while institutional investors hold 82.90% of the company’s shares. The shares outstanding are 137.00M, and float is at 128.95M with Short Float at 2.35%. Institutions hold 78.62% of the Float.
The top institutional shareholder in the company is Viking Global Investors, L.P. with over 29.99 million shares valued at $1.77 billion. The investor’s holdings represent 21.93% of the ADPT Shares outstanding. As of Dec 30, 2020, the second largest holder is Matrix Capital Management with 13.12 million shares valued at $775.5 million to account for 9.59% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 9.66 million shares representing 7.06% and valued at over $570.93 million, while Price (T.Rowe) Associates Inc holds 4.35% of the shares totaling 5.95 million with a market value of $352.11 million.
Adaptive Biotechnologies Corporation (ADPT) Insider Activity
A total of 522 insider transactions have happened at Adaptive Biotechnologies Corporation (ADPT) in the last six months, with sales accounting for 355 and purchases happening 167 times. The most recent transaction is an insider sale by Taylor Stacy L, the company’s SVP and General Counsel. SEC filings show that Taylor Stacy L sold 2,812 shares of the company’s common stock on Feb 26 at a price of $55.53 per share for a total of $0.16 million. Following the sale, the insider now owns 1300.0 shares.
Adaptive Biotechnologies Corporation disclosed in a document filed with the SEC on Feb 26 that RUBINSTEIN JULIE (President) sold a total of 15,000 shares of the company’s common stock. The trade occurred on Feb 26 and was made at $56.23 per share for $0.84 million. Following the transaction, the insider now directly holds 0.0 shares of the ADPT stock.
Still, SEC filings show that on Feb 25, RUBINSTEIN JULIE (President) disposed off 14,675 shares at an average price of $56.18 for $0.82 million. The insider now directly holds 0 shares of Adaptive Biotechnologies Corporation (ADPT).